Where does Portola Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Portola Pharmaceuticals, Inc. ranks #9,590 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Portola Pharmaceuticals, Inc. hold?

Portola Pharmaceuticals, Inc. holds 33 US utility patents granted between 2015 and 2020, spanning 9 technology areas.

What is Portola Pharmaceuticals, Inc.'s Innovation Score?

Portola Pharmaceuticals, Inc. has an Innovation Score of 32.3 out of 100 (41st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Portola Pharmaceuticals, Inc. focus on?

Portola Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 29 patents, ranking #678 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Portola Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Portola Pharmaceuticals, Inc.'s recent grant velocity is -78% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Portola Pharmaceuticals, Inc.'s patents?

Portola Pharmaceuticals, Inc.'s patents average 15.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Portola Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Portola Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 33 granted patents across 9 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Portola ranks #9,590 of 49,997 tracked US assignees by granted-patent volume, with 33 patents across 9 technology areas.

#9,590
of 49,997 US assignees by volume: 41st percentile
by Innovation Score (32.3/100): 15.9
avg claims per patent: -78%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9590 · US Corporation #9,590 · 33 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 33 grants
UPPER-Q #9,590/49,997
PHOTO-FINISH Par Pharmaceutical
CPC-NARROW A61P · 9 areas
INNOV-THIN 32.3/100
CLAIMS-RICH 15.9 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -78% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Par Pharmaceutical, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Portola’s 32.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.2 pts (38%) Velocity 0.0 pts (0%) Breadth 10.6 pts (33%) Claim depth 9.5 pts (29%)

Qualcomm Incorporated · highest

85
Domo · near

32
Novimmune · near

32
Portola Pharmaceutic… · this assignee

32
SPD Swiss Precision… · near

32
Stat Medical Devices · near

32
3D Lighting… · lowest

7

What this shows Portola's Innovation Score is 32.3/100 (41st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Portola?

Each dot is one of Portola’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Portola’s own 15.9 claims/patent is at or below the 16.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Portola vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Portola's grants concentrate

Portola Pharmaceuticals, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 87.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (14 grants) versus a trough of 1 in 2019. By volume, Portola sits between Par Pharmaceutical, Inc. and Qatar Foundation.

Par Pharmaceutical

33
Patreon

33
Polder Products

33
Portal Instruments

33
Qbase

33
Qingdao Goertek T…

33
Quanzhou Sanan Se…

33
Qatar Foundation

33
Portola Pharmaceu… ◀

33

What this shows Portola holds 33 patents at rank #9,590, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Portola

By rank, the assignees closest to #9,590 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Portola's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Portola, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Portola ranks #678 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Novimmune SA 32 SPD Swiss Precision Diagnostics GMBH 32 Domo, Inc. 32 Stat Medical Devices, Inc. 32

Portola's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 41st percentile higher than 41% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Portola Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	14	42.4%
2016	4	12.1%
2017	6	18.2%
2018	2	6.1%
2019	1	3.0%
2020	6	18.2%

Which technologies does Portola Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 29

C07D - Heterocyclic Compounds 21

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 11

C12Y - Enzymes 9

C07K - Peptides 4

C07C - Acyclic OR Carbocyclic Compounds 2

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

B01D - Separation 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Portola Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Portola Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #9,590 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Portola Pharmaceuticals, Inc. against Par Pharmaceutical, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.